Lee, Colin Y. C. http://orcid.org/0000-0001-8380-4917
Kennedy, Bethany C. http://orcid.org/0000-0001-9529-7545
Richoz, Nathan
Dean, Isaac http://orcid.org/0000-0002-4750-5335
Tuong, Zewen K.
Gaspal, Fabrina
Li, Zhi http://orcid.org/0000-0002-0583-1116
Willis, Claire
Hasegawa, Tetsuo
Whiteside, Sarah K.
Posner, David A.
Carlesso, Gianluca
Hammond, Scott A. http://orcid.org/0000-0001-5800-4328
Dovedi, Simon J.
Roychoudhuri, Rahul http://orcid.org/0000-0002-5392-1853
Withers, David R. http://orcid.org/0000-0003-3757-7594
Clatworthy, Menna R. http://orcid.org/0000-0002-3340-9828
Funding for this research was provided by:
Wellcome Trust (220268/Z/20/Z)
Cancer Research UK (C54019/A27535)
Article History
Received: 27 April 2023
Accepted: 2 January 2024
First Online: 24 January 2024
Competing interests
: AstraZeneca provided therapeutic anti-PD-L1 antibodies, isotype control antibodies, and MC38-Ova cells. GC, SAH and SJD are full employees and shareholders in AstraZeneca. No other disclosures or conflicts of interest are reported.